Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)(COMPLETED)

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
First received: June 1, 2007
Last updated: May 21, 2013
Last verified: May 2013

Efficacy and Safety Study of MK0359 in Patients with Arthritis

Condition Intervention Phase
Rheumatoid Arthritis
Drug: MK0359
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: December 2002
Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • You are 18-65 years of age and have Rheumatoid Arthritis
  • You must be able to read and understand patient questionnaires

Exclusion Criteria:

  • You have had certain types of surgery, certain types of cancer or history of Tuberculosis (TB) or HIV.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00482417

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00482417     History of Changes
Other Study ID Numbers: 2007_573
Study First Received: June 1, 2007
Last Updated: May 21, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on April 22, 2014